JTO Clinical and Research Reports (Jul 2021)

The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer

  • Barbara J. Gitlitz, MD,
  • Silvia Novello, MD, PhD,
  • Tiziana Vavalà, MD,
  • Marisa Bittoni, PhD,
  • Alicia Sable-Hunt, RN, MBA,
  • Dean Pavlick, BS,
  • Robert Hsu, MD,
  • S. Lani Park, PhD, MPH,
  • Ruthia Chen, BA,
  • Matthew Cooke, BA,
  • Amy Moore, PhD,
  • Alexa B. Schrock, PhD,
  • Joan H. Schiller, MD,
  • Bonnie J. Addario,
  • Geoffrey R. Oxnard, MD

Journal volume & issue
Vol. 2, no. 7
p. 100194

Abstract

Read online

Introduction: Lung adenocarcinomas in young patients (<40 y) are more likely to harbor targetable genomic alterations. This study aimed to determine whether the prevalence of targetable alterations is greater in young adults with lung carcinoma than in the overall lung cancer population. To reach this rare patient population, a web-based platform was used to recruit and enroll patients remotely. Methods: In this prospective study, patients less than 40 years old at the time of primary lung cancer diagnosis with confirmed lung carcinoma were recruited from four global sites and remotely by means of a website. Genotyping data were collected, if available, or obtained by means of next-generation sequencing using the FoundationOne platform. The prevalence of targetable alterations was quantified across patients with advanced adenocarcinoma. Results: Overall, 133 patients across five continents were included, 41% of whom enrolled online. The mean (SD) age at diagnosis was 34 (5.2) years; 79% had stage IV disease at diagnosis. Among patients with adenocarcinoma (n = 115), 112 entered the study with previous genomic testing results and 86 (77%) had targetable alterations in EGFR, ALK, ROS1, MET, ERBB2, or RET. Among those without targetable alterations, 14 received further testing and a targetable alteration was identified in eight (57%). Conclusions: This study revealed the feasibility of using a web-based platform to recruit young patients with lung cancer and revealed that 94 of 112 (84%) with adenocarcinoma at any stage had targetable genomic alterations. Among patients with stage IV adenocarcinoma, 85% had a targetable alteration, which is higher than historical expectations for the general population.

Keywords